Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis

Published:January 17, 2018DOI:


      • Both MOG-ab disease and NMOSD can co-exist NMDARe.
      • MOG-ab disease more commonly co-exist NMDARe than NMOSD.
      • When co-existing NMDARe, MOG-ab disease responds better to steroids/IVIG than NMOSD.



      Myelin oligodendrocyte glycoprotein (MOG)-antibody (ab) disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) can co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis (NMDARe).


      To characterize MOG-ab disease and AQP4-IgG-positive NMOSD during NMDARe.


      We analyzed all the patients with overlapping MOG-ab disease and NMDARe (MNOS) and patients with AQP4-IgG-positive NMOSD and NMDARe (ANOS) in our hospital and compared those data with data from systematically review of previously published reports.


      In our cohorts, 11.9% patients with MOG-ab disease and 0.6% patients with NMOSD had overlapping NMDARe (P < 0.01). After treatment with steroids and/or intravenous immunoglobulin (IVIg), the median modified Rankin Scale (mRS) of the MNOS group decreased significantly during attacks associated with or without NMDARe (P < 0.01 for both), while that of the ANOS group did not (attack: P < 0.05; attack associated with NMDARe: P > 0.05). Analyzed together with previously reported cases, 6% patients with MNOS and 40% patients with ANOS also used rituximab or cyclophosphamide after steroids and/or IVIg (P < 0.05) during attacks associated with NMDARe.


      Compared with NMOSD, MOG-ab disease may more commonly co-exist with NMDARe. MNOS patients respond better to steroids and IVIg than do ANOS patients during attacks associated with NMDARe.


      ab (antibody), ANOS (the overlapping syndrome of AQP4-IgG-positive NMOSD and NMDARe), AQP4 (aquaporin-4), CBAs (cell-based assays), CNS (central nervous system), CSF (cerebrospinal fluid), EDSS (Expanded isability Status Scale), IgG (immunoglobulin G), IIFT (immune-fluorescence test), MNOS (the overlapping syndrome of MOG-ab disease and NMDARe), mRS (modified Rankin Scale), MOG (myelin oligodendrocyte glycoprotein), MRI (magnetic resonance imaging), MS (multiple sclerosis), NMDA (N-methyl-D-aspartate), NMDARe (NMDA receptor encephalitis), NMOSD (neuromyelitis optica spectrum disorder)


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Asgari N.
        • Jarius S.
        • Laustrup H.
        • et al.
        Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: a predominantly population-abased study.
        Mult. Scler. 2017;
        • Asgari N.
        • Owens T.
        • Frøkiǽr J.
        • Stenager E.
        • Lillevang S.T.
        • Kyvik K.O.
        Neuromyelitis optica (NMO) - an autoimmune disease of the central nervous system (CNS).
        Acta Neurol. Scand. 2011; 123: 369-384
        • Dale R.C.
        • Tantsis E.M.
        • Merheb V.
        • et al.
        Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton.
        Neurol. Neuroimmunol. Neuroinflamm. 2014; 1: e12
        • Dalmau J.
        • Lancaster E.
        • Martinez-Hernandez E.
        • Rosenfeld M.R.
        • Balice-Gordon R.
        Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis.
        Lancet Neurol. 2011; 10: 63-74
        • Graus F.
        • Titulaer M.J.
        • Balu R.
        • et al.
        A clinical approach to diagnosis of autoimmune encephalitis.
        Lancet Neurol. 2016; 15: 391-404
        • Hacohen Y.
        • Absoud M.
        • Hemingway C.
        • et al.
        NMDA receptor antibodies associated with distinct white matter syndromes.
        Neurol. Neuroimmunol. Neuroinflamm. 2014; 1: e2
        • Honda K.
        • Yuasa T.
        A case of anti-aquaporin-4 and anti-glutamate receptor antibodies positive myelitis presented with modest clinical signs.
        Magn. Reson. Med. Sci. 2008; 7: 55-58
        • Ikeda K.
        • Kiyota N.
        • Kuroda H.
        • et al.
        Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody.
        Mult. Scler. 2015; 21: 656-659
        • Jarius S.
        • Ruprecht K.
        • Kleiter I.
        • et al.
        MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
        J. Neuroinflamm. 2016; 13: 279
        • Jarius S.
        • Ruprecht K.
        • Kleiter I.
        • et al.
        MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
        J. Neuroinflamm. 2016; 13: 280
        • Jurynczyk M.
        • Geraldes R.
        • Probert F.
        • et al.
        Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis.
        Brain. 2017; 140: 617-627
        • Kaneko K.
        • Sato D.K.
        • Misu T.
        • et al.
        Anti-N-methyl-D-aspartate receptor encephalitis with multiphasic demyelination.
        Ann. Neurol. 2014; 76: 462-464
        • Kim S.M.
        • Woodhall M.R.
        • Kim J.S.
        • et al.
        Antibodies to MOG in adults with inflammatory demyeliating disease of the CNS.
        Neurol. Neuroimmunol. Neuroinflamm. 2015; 2: e163
        • Kim W.
        • Park M.S.
        • Lee S.H.
        • et al.
        Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity.
        Mult. Scler. 2010; 16: 1229-1236
        • Kitley J.
        • Waters P.
        • Woodhall M.
        • et al.
        Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
        JAMA Neurol. 2014; 71: 276-283
        • Leite M.I.
        • Coutinho E.
        • Lana-Peixoto M.
        • et al.
        Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients.
        Neurology. 2012; 78: 1601-1607
        • Lipton S.A.
        NMDA receptors, glial cells, and clinical medicine.
        Neuron. 2006; 50: 9-11
        • Lucchinetti C.F.
        • Guo Y.
        • Popescu B.F.
        • Fujihara K.
        • Itoyama Y.
        • Misu T.
        The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica.
        Brain Pathol. 2014; 24: 83-97
        • Luo J.J.
        • Lv H.
        • Sun W.
        • et al.
        Anti-N-methyl-d-aspartate receptor encephalitis in a patient with neuromyelitis optica spectrum disorders.
        Mult. Scler. Relat. Disord. 2016; 8: 74-77
        • Peschl P.
        • Bradl M.
        • Hoftberger R.
        • Berger T.
        • Reindl M.
        Myelin oligodendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases.
        Front Immunol. 2017; 8: 529
        • Pittock S.J.
        • Lennon V.A.
        • de Seze J.
        • et al.
        Neuromyelitis optica and non organ-specific autoimmunity.
        Arch. Neurol. 2008; 65: 78-83
        • Qin K.
        • Wu W.
        • Huang Y.
        • et al.
        Anti-N-methyl-D-aspartate receptor(NMDAR) antibody encephalitis presents in atypical types and coexists with neuromyelitis optica spectrum disorder or neurosyphilis.
        BMC Neurol. 2017; 17: 1
        • Ramanathan S.
        • Dale R.C.
        • Brilot F.
        Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination.
        Autoimmun. Rev. 2016; 15: 307-324
        • Ran Y.
        • Wang L.
        • Zhang F.
        • Ao R.
        • Dong Z.
        • Yu S.
        Anti-NMDAR encephalitis followed by seropositive neuromyelitis optica spectrum disorder: a case report and literature review.
        Clin. Neurol. Neurosurg. 2017; 155: 75-82
        • Sato D.K.
        • Callegaro D.
        • Lana-Peixoto M.A.
        • et al.
        Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
        Neurology. 2014; 82: 474-481
        • Siritho S.
        • Sato D.K.
        • Kaneko K.
        • Fujihara K.
        • Prayoonwiwat N.
        The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients.
        Mult. Scler. 2016; 22: 964-968
        • Titulaer M.J.
        • Hoftberger R.
        • Iizuka T.
        • et al.
        Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis.
        Ann. Neurol. 2014; 75: 411-428
        • Titulaer M.J.
        • McCracken L.
        • Gabilondo I.
        • et al.
        Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study.
        Lancet Neurol. 2013; 12: 157-165
        • Wang J.J.
        • Jaunmuktane Z.
        • Mummery C.
        • Brandner S.
        • Leary S.
        • Trip S.A.
        Inflammatory demyelination without astrocyte loss in MOG antibody-positive NMOSD.
        Neurology. 2016; 87: 229-231
        • Watanabe M.
        • Kondo T.
        • Murakata K.
        • et al.
        Antibodies to neural and non-neural autoantigens in Japanese patients with CNS demyelinating disorders.
        J. Neuroimmunol. 2014; 274: 155-160
        • Wingerchuk D.M.
        • Banwell B.
        • Bennett J.L.
        • et al.
        International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
        Neurology. 2015; 85: 177-189
        • Xu Y.
        • Wang Q.
        • Ren H.T.
        • et al.
        Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: a prospective cohort study.
        J. Neurol. Sci. 2016; 370: 224-228
        • Yokoyama K.
        • Hori M.
        • Yoshida A.
        Anti-myelin oligodendrocyte glycoprotein antibody neuritis optica following anti-NMDA receptor encephalitis.
        Pediatr. Int. 2016; 58: 953-954
        • Zhou L.
        • Huang Y.
        • Li H.
        • et al.
        MOG-antibody associated demyelinating disease of the CNS: a clinical and pathological study in Chinese Han patients.
        J. Neuroimmunol. 2017; 305: 19-28
        • Zoccarato M.
        • Saddi M.V.
        • Serra G.
        • et al.
        Aquaporin-4 antibody neuromyelitis optica following anti-NMDA receptor encephalitis.
        J. Neurol. 2013; 260: 3185-3187